AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30614286 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plaster (700 mg)
Number of subjects: 363
Study 30614286 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 363
Study 30614286 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine plaster vs Placebo
Number of subjects: 363
Study 29547163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization of the outer cavernous sinus membrane
Number of subjects: 94
Study 29547163 — intervention group
Group type: COMPARATOR
Intervention: Direct opening of the dura without cavernous sinus dissection
Number of subjects: 94
Study 27389172 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-16 inoculation in seronegative subjects
Number of subjects: 40
Study 27389172 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-16 inoculation in seropositive subjects
Number of subjects: 40
Study 27389172 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-16 inoculation in both sexes
Number of subjects: 40
Study 24863037 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4% LSO toothpaste
Number of subjects: 81
Study 24863037 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4% LSO gel
Number of subjects: 81
Study 24863037 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% LSO mouthwash
Number of subjects: 81
Study 24863037 — intervention group
Group type: COMPARATOR
Intervention: 1% chlorhexidine gel
Number of subjects: 81
Study 24863037 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash
Number of subjects: 81
Study 22497874 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 (Rotarix™)
Number of subjects: 10708
Study 21078493 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-dsDNA antibodies
Number of subjects: 245
Study 21078493 — intervention group
Group type: EXPERIMENTAL
Intervention: antinucleosome antibodies
Number of subjects: 245
Study 21078493 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-C1q antibodies
Number of subjects: 245
Study 18647285 — intervention group
Group type: EXPERIMENTAL
Intervention: AFI
Number of subjects: 167
Study 18647285 — intervention group
Group type: COMPARATOR
Intervention: WL
Number of subjects: 167
Study 16941030 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib, 400 mg b.i.d.
Number of subjects: 7968
Study 16941030 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac, 75 mg b.i.d.
Number of subjects: 7968
Study 16941030 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen, 800 mg three times a day.
Number of subjects: 7968
Study 13130321 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week exercise program with active exercise, muscle stretching, and treadmill walking
Number of subjects: 18
Study 13130321 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study 10935770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IP)
Number of subjects: 40
Study 10935770 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 9361575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management by culturally sensitive community health educators
Number of subjects: 0
Study 9361575 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 1489126 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (28 mg)
Number of subjects: 12
Study 1489126 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled torasemide (28 mg)
Number of subjects: 12
Study 1489126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3563116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium 100 micrograms
Number of subjects: 24
Study 3563116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium 200 micrograms
Number of subjects: 24
Study 3563116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium 300 micrograms
Number of subjects: 24
Study 3563116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 400 micrograms
Number of subjects: 24
Study 3563116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium 200 micrograms plus Fenoterol 400 micrograms
Number of subjects: 24
Study 3563116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium 200 micrograms and 300 micrograms
Number of subjects: 24
Study 3563116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol plus Oxitropium
Number of subjects: 24
Study 3563116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30646197 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy/individualized exercise
Number of subjects: 259
Study 30646197 — intervention group
Group type: COMPARATOR
Intervention: Medical care
Number of subjects: 259
Study 30646197 — intervention group
Group type: COMPARATOR
Intervention: Group exercise
Number of subjects: 259
Study 30646197 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 259
Study 30286707 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher peer specialist engagement
Number of subjects: 140
Study 30286707 — intervention group
Group type: COMPARATOR
Intervention: Lower peer specialist engagement
Number of subjects: 140
Study 30286707 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 26671629 — intervention group
Group type: EXPERIMENTAL
Intervention: VR simulation training (7.5 hours)
Number of subjects: 18
Study 26671629 — intervention group
Group type: COMPARATOR
Intervention: Control group (4.5 hours of lectures)
Number of subjects: 18
Study 24561636 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week neck strengthening intervention performed twice per week
Number of subjects: 25
Study 24561636 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 semiprofessional players)
Number of subjects: 25
Study 23164333 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Tooth Anesthesia System (STA System)
Number of subjects: 100
Study 23164333 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe technique
Number of subjects: 100
Study 19965781 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily)
Number of subjects: 30
Study 19965781 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 30
Study 19965781 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 17389164 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP + FET
Number of subjects: 32
Study 17389164 — intervention group
Group type: COMPARATOR
Intervention: FET
Number of subjects: 32
Study 16127682 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended transthoracic oesophagectomy
Number of subjects: 50
Study 12401635 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia
Number of subjects: 50
Study 12401635 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 50
Study 10087420 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxium (calcium dobesilate) 2 g daily until delivery
Number of subjects: 23
Study 10087420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10087420 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxium (calcium dobesilate)
Number of subjects: 23
Study 8628838 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgambond Plus with HPA
Number of subjects: 0
Study 2333739 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 1.3 g protein/dl and 55:45 whey: casein ratio
Number of subjects: 0
Study 2333739 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 1.4 g/dl protein; 55:45 whey: casein ratio
Number of subjects: 0
Study 2333739 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 1.5 g/dl protein; 55:45 whey: casein ratio
Number of subjects: 0
Study 2333739 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 1.4 g/dl protein; 60:40 whey: casein ratio
Number of subjects: 0
Study 2333739 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 1.4 g/dl protein; 20:80 whey: casein ratio
Number of subjects: 0
Study 2333739 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulas containing 0.7 mg iron and 0.7 mg zinc/dl
Number of subjects: 0
Study 2333739 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed group
Number of subjects: 0
Study 453775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (Pz) 2 mg t.i.d.
Number of subjects: 17
Study 453775 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (MD) 250 mg t.i.d.
Number of subjects: 17
Study 453775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (Pz) + Methyldopa (MD)
Number of subjects: 17
Study 453775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (Pz) + Clonidine (C)
Number of subjects: 17
Study 453775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (Pz) + Propranolol
Number of subjects: 17
Study 453775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (Pz) + Diuretic
Number of subjects: 17
Study 453775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30183409 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education (4 sessions of 45 minutes each)
Number of subjects: 70
Study 30183409 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 70
Study 27640922 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose shockwave therapy
Number of subjects: 28
Study 27640922 — intervention group
Group type: COMPARATOR
Intervention: Sham dose
Number of subjects: 28
Study 26299931 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100F-HMP1% toothpaste
Number of subjects: 12
Study 26299931 — intervention group
Group type: COMPARATOR
Intervention: 1100ppm F (1100F) toothpaste
Number of subjects: 12
Study 26299931 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no F or HMP)
Number of subjects: 12
Study 22781558 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV + nebulizer group
Number of subjects: 21
Study 22781558 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 20471117 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin loading before PCI
Number of subjects: 445
Study 20471117 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment before PCI (control group)
Number of subjects: 445
Study 19491814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladasten
Number of subjects: 0
Study 19491814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17260161 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of hyperammonemia by administration of a solution mimicking the amino acid composition of haemoglobin (60)
Number of subjects: 84
Study 17260161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24)
Number of subjects: 84
Study 17260161 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of hyperammonemia
Number of subjects: 84
Study 14696754 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 or 60 mg folic acid with or without vitamins B6 and B12 for eight weeks
Number of subjects: 114
Study 14696754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous folinic acid given alone or with serine for eight weeks
Number of subjects: 114
Study 14696754 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos for both protocols
Number of subjects: 114
Study 10863071 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation
Number of subjects: 445
Study 10863071 — intervention group
Group type: COMPARATOR
Intervention: Accelerated fractionation
Number of subjects: 445
Study 10863071 — intervention group
Group type: EXPERIMENTAL
Intervention: RPA Class II (Accelerated hyperfractionation)
Number of subjects: 445
Study 10863071 — intervention group
Group type: COMPARATOR
Intervention: RPA Class II (Accelerated fractionation)
Number of subjects: 445
Study 9191629 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials (medication booklet, behavioral health booklet, video)
Number of subjects: 108
Study 1337161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol (0.5 micrograms/day) for 8 weeks
Number of subjects: 31
Study 1337161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1337161 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 31
Study 3799228 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamiro
Number of subjects: 150
Study 3799228 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque
Number of subjects: 150
Study 3799228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 150
Study 30699443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercurius corrosivus (Merc-c.) at potency levels 24x to 30x
Number of subjects: 0
Study 30699443 — intervention group
Group type: COMPARATOR
Intervention: Water controls (unsuccussed and succussed water)
Number of subjects: 0
Study 30699443 — intervention group
Group type: COMPARATOR
Intervention: Systematic negative control (SNC) experiments
Number of subjects: 0
Study 28384657 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy (4-drug oral regimen: daily celecoxib and thalidomide with alternating periods of etoposide and cyclophosphamide)
Number of subjects: 108
Study 28384657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 28384657 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy (4-drug oral regimen)
Number of subjects: 108
Study 25670360 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil (CO)
Number of subjects: 54
Study 25670360 — intervention group
Group type: COMPARATOR
Intervention: Extra-virgin olive oil (EVOO)
Number of subjects: 54
Study 23404155 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy (LG) with D2 lymphadenectomy
Number of subjects: 204
Study 21916354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice formulated with silicas (test)
Number of subjects: 125
Study 21916354 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste (control)
Number of subjects: 125
Study 19556076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory re-education program (Group A)
Number of subjects: 40
Study 19556076 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Group B)
Number of subjects: 40
Study 19556076 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 16478755 — intervention group
Group type: COMPARATOR
Intervention: 300 mg l-dopa
Number of subjects: 18
Study 16478755 — intervention group
Group type: COMPARATOR
Intervention: 1.25 mg bromocriptine
Number of subjects: 18
Study 16478755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15598116 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression with low cognitive load
Number of subjects: 0
Study 15598116 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression with high cognitive load
Number of subjects: 0
Study 15598116 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment anxiety
Number of subjects: 0
Study 11157334 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate energy-restricted diet (WL group)
Number of subjects: 27
Study 9771303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine 0.02 mg kg‐1 (Group A, n = 25)
Number of subjects: 77
Study 9771303 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.004 mg kg‐1 (Group G, n = 27)
Number of subjects: 77
Study 9771303 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (Group P, n = 25)
Number of subjects: 77
Study 7834593 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training in the clinic only
Number of subjects: 28
Study 7834593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of four sessions in the clinic, four sessions in real-life, and six follow-up sessions in the clinic
Number of subjects: 28
Study 7834593 — intervention group
Group type: COMPARATOR
Intervention: Social skills training (both groups)
Number of subjects: 28
Study 3401658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ampicillin and 80 mg gentamicin pre‐operatively
Number of subjects: 93
Study 3401658 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 93
Study 29263079 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time therapeutic drug monitoring (TDM) with same-day real-time dose adaptation
Number of subjects: 40
Study 29263079 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group (no real-time TDM)
Number of subjects: 40
Study 26654125 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized immunonutrition (SIM)
Number of subjects: 29
Study 26654125 — intervention group
Group type: COMPARATOR
Intervention: Oral nutrition supplement (ONS)
Number of subjects: 29
Study 25232713 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible 19G needle
Number of subjects: 100
Study 25232713 — intervention group
Group type: COMPARATOR
Intervention: Flexible 25G needle
Number of subjects: 100
Study 23047542 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial insulin aspart (Asp)
Number of subjects: 12
Study 23047542 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial insulin glulisine (Glu)
Number of subjects: 12
Study 22249875 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive acoustic stimulation and analysis
Number of subjects: 5
Study 19111551 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 70
Study 19111551 — intervention group
Group type: COMPARATOR
Intervention: Gluten-containing diet
Number of subjects: 70
Study 16967595 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid and dipyridamole (30‐325 mg daily and 200 mg twice daily)
Number of subjects: 2739
Study 16967595 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid only (30‐325 mg daily)
Number of subjects: 2739
Study 16967595 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid and dipyridamole
Number of subjects: 2739
Study 15518751 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at doses of 0.5, 1, 1.5, and 2 g/day
Number of subjects: 46
Study 11561938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg/day
Number of subjects: 14
Study 11561938 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 14
Study 9258756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground-Reaction Forces (GRF) exercise program
Number of subjects: 39
Study 9258756 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint-Reaction Forces (JRF) exercise program
Number of subjects: 39
Study 9258756 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 39
Study 7683447 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml hydroxyethyl starch (HAES)
Number of subjects: 12
Study 7683447 — intervention group
Group type: COMPARATOR
Intervention: 500 ml NaCl 0.9%
Number of subjects: 12
Study 3128362 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 36
Study 3128362 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide anaesthesia
Number of subjects: 36
Study 29281798 — intervention group
Group type: EXPERIMENTAL
Intervention: NoCL (patients without unstable chondral lesions)
Number of subjects: 0
Study 29281798 — intervention group
Group type: EXPERIMENTAL
Intervention: NoCL
Number of subjects: 0
Study 29281798 — intervention group
Group type: COMPARATOR
Intervention: CL‐noDeb (patients with unstable chondral lesions left in situ)
Number of subjects: 0
Study 28763550 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact aspiration (n=192)
Number of subjects: 381
Study 28763550 — intervention group
Group type: COMPARATOR
Intervention: Stent retriever (n=189)
Number of subjects: 381
Study 25658671 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-alert training (SAT)
Number of subjects: 0
Study 25658671 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23829776 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 358
Study 23829776 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance
Number of subjects: 358
Study 23829776 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait velocity
Number of subjects: 358
Study 23829776 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD)
Number of subjects: 358
Study 16884369 — intervention group
Group type: EXPERIMENTAL
Intervention: New cervical cell sampler (the implement)
Number of subjects: 200
Study 16884369 — intervention group
Group type: COMPARATOR
Intervention: Cervex brush
Number of subjects: 200
Study 16884369 — intervention group
Group type: COMPARATOR
Intervention: Both devices (new implement and cervex brush)
Number of subjects: 200
Study 12952113 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (administered every 2 or 4 weeks for 52 weeks)
Number of subjects: 309
Study 12952113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered for 28 weeks)
Number of subjects: 309
Study 10543320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea plus didanosine (ddI) at a dosage of 500 mg twice a day for at least 40 weeks
Number of subjects: 40
Study 7776857 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐a2b subcutaneously three times weekly for 12 months (5 MU/m2 for 4 months and then 3 MU/m2 for a further 8 months)
Number of subjects: 22
Study 7776857 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐a2b
Number of subjects: 22
Study 7776857 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 22
Study 2406863 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Number of subjects: 50
Study 2406863 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 50
Study 2406863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7472292 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexigenic drugs (phenmetrazine)
Number of subjects: 4
Study 7472292 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexigenic drugs (phentermine)
Number of subjects: 4